NASDAQ Companies

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation […]

WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage […]

EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic […]

HOLLYWOOD, Fla., March 04, 2024 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of […]

7.9 EH/s of installed and operational self-mining capacity Building 4 (35 MW) at Lake Mariner advancing construction, providing path to […]

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages 2-5 with […]

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today […]

RENO, Nev., March 04, 2024 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, […]

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on […]

DALLAS, March 04, 2024 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a global leader of access, optical and AI-driven cloud software […]